iStock_000083594879_Medium.jpg

A NEW WAY OF TARGETING INFLAMMATORY DISEASE

Alivio Therapeutics is advancing a platform technology that could enhance the treatment of inflammatory diseases.

Alivio Therapeutics is developing novel drug formulations for treating inflammatory diseases. There are numerous conditions caused by chronic inflammation which represent multibillion dollar markets. Despite the magnitude of the unmet need and the substantial progress in basic research, few truly novel drugs have come to market in the last decade. A major complicating factor has been that the pathways that modulate inflammation act broadly – so that agents that seek to dampen inflammation locally can have substantial side effects and toxicity.

Alivio is developing a new solution to the delivery problem in inflammation. Alivio’s technology platform is a proprietary delivery technology that is designed to entrap a broad array of bioactives, target them to inflamed tissue, and then release them to a greater or lesser degree based on the amount of inflammation that is present.  The technology was developed by biomaterials pioneers Jeffrey Karp, PhD and Robert Langer, ScD. The novel properties of the technology have been published twice in Science Translational Medicine

OUR TEAM

Jeff Karp, Ph.D.
Member of the Scientific Advisory Board

Dr. Jeff Karp is a co‐founder of Alivio Therapeutics and is an Associate Professor at Brigham and Women’s Hospital, Harvard Medical School. He has published more than 100 peer‐reviewed papers, has given over 200 national and international ...


Robert Langer, Sc.D.
Member of the Scientific Advisory Board and Board of Directors

Dr. Robert Langer is a co-founder of Alivio Therapeutics and is known for his groundbreaking discoveries in the fields of polymer chemistry, controlled drug delivery, and tissue engineering. He is the David H. Koch Institute Professor at the Massachusetts Institute of Technology...


Michael B. Brenner, M.D.
Member of the Scientific Advisory Board

Dr. Michael Brenner is the Theodore B. Bayles Professor of Medicine at Harvard Medical School. Dr. Brenner is also the Chief of the Division of Rheumatology, Immunology, and Allergy at the Brigham and Women’s Hospital. Dr. Brenner and his laboratory have made ... 


Ivana Magovcevic‐Liebisch, Ph.D., J.D.
Member of the Board of Directors

Dr. Ivana Magovcevic-Liebisch is Senior Vice President and Head of Global Business Development at Teva Pharmaceuticals. In this capacity, Ivana is responsible for the execution of transactions identified by Teva’s R&D, Global Franchises ...


Ulrich H. von Andrian, M.D., Ph.D.
Member of the Scientific Advisory Board

Dr. Ulrich von Andrian is the Mallinckrodt Professor of Immunopathology at Harvard Medical School.  Dr. von Andrian’s scientific research is focused on the regulation and function of immune cells in health and disease. Dr. von Andrian ...


Ralph Weissleder, M.D., Ph.D.
Member of the Scientific Advisory Board

Dr. Ralph Weissleder is the Thrall Professor of Radiology and Professor of Systems Biology at Harvard Medical School, Director of the Center for Systems Biology at Massachusetts General Hospital (MGH), and Attending Clinician ...


Eric Elenko, Ph.D.
Member of the Board of Directors

Dr. Eric Elenko is a co-founder  of Alivio Therapeutics and the Executive Vice President of Science and Technology at PureTech. Dr. Elenko has co-founded a number of companies at PureTech for which he has acted as a board member ...


Aleks Radovic-Moreno, PH.D.

Dr. Radovic-Moreno is a co-founder of Alivio Therapeutics and a Senior Associate at PureTech. He was previously a Research Scientist at the biotech startup AuraSense Therapeutics , where he was a lead inventor of the company's core immunotherapy ...

CONTACT US

info@aliviotherapeutics.com

Alivio Therapeutics

501 Boylston Street | Suite 6102 | Boston, MA 02116